Loading
Gestational Diabetes Research and Management / Ovarian Function and Disorders · Journal article
F1000research · August 6, 2026
A consensus or society position rather than new primary data.
This is a narrative critical review examining liraglutide's role in weight management and reproductive outcomes in women with obesity and PCOS. The source synthesizes mechanistic evidence suggesting liraglutide promotes weight loss, restores menstrual cyclicity, and improves natural conception and ART response rates through endocrine regulation and anti-inflammatory effects, while noting significant unresolved questions about long-term efficacy, offspring health, and practical barriers to use.
Narrative literature review. Literature on liraglutide use in women with obesity and PMOS; specific inclusion/exclusion criteria not stated.. Intervention: Liraglutide for weight management and reproductive health.
Liraglutide promotes greater weight loss and improves reproductive outcomes in women with obesity and PMOS Mechanism involves regulating endocrine parameters, reducing systemic inflammation, restoring menstrual cyclicity, and supporting folliculogenesis Improves outcomes by increasing natural conception rates and improving responses to assisted reproductive techniques
Long-term safety and offspring health data explicitly identified as lacking by authors Major limitations include need for daily subcutaneous injections, cost, and gastrointestinal adverse effects
Clinicians considering liraglutide for this population should recognize accumulated evidence of reproductive benefit through metabolic improvement, but acknowledge substantial evidence gaps regarding sustained long-term efficacy, offspring outcomes, and practical feasibility factors that currently limit clinical adoption.
A critical narrative review synthesizing mechanistic evidence and clinical findings on liraglutide for weight management and reproductive health in women with obesity and PMOS, offering clinical perspective rather than reporting original trial data.
As stated by the source record.
Clinicians considering liraglutide for this population should recognize accumulated evidence of reproductive benefit through metabolic improvement, but acknowledge substantial evidence gaps regarding sustained long-term efficacy, offspring outcomes, and practical feasibility factors that currently limit clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity and polyendocrine metabolic ovarian syndrome (PMOS) in women are associated with significant reproductive dysfunction, manifesting as hormonal imbalances, anovulation, and subfertility. These conditions not only impair reproductive outcomes but also contribute to a reduced quality of life. Crucially, obesity and PMOS share a bidirectional relationship. While obesity can trigger and worsen PMOS manifestations, the convergence of these two conditions has contributed significantly to the growing incidence of female infertility. This review critically examines liraglutide’s mechanistic role and therapeutic potential in mediating metabolic restoration and improving the fertility outcomes in women burdened by obesity and PMOS. A literature search was conducted in original databases from inception until March 2025 in PubMed, Google Scholar, Cochrane Library, Scopus, and Web of Science using the following keywords pertinently: “GLP-1R”, “liraglutide”, “female reproductive system”, “polyendocrine metabolic syndrome”, “ovarian function”, and “pregnancy outcomes”. Accumulated evidence suggests that liraglutide promotes greater weight loss and improves reproductive outcomes in women with obesity and PMOS by regulating endocrine parameters, reducing systemic inflammation, restoring menstrual cyclicity, and supporting folliculogenesis. It improves reproductive outcomes by increasing natural conception rates and improving responses to assisted reproductive techniques (ART). However, with all the positive outcomes, the major limitations of using this drug for weight loss are the need for daily subcutaneous injections, cost, and gastrointestinal adverse effects. Long-term assessment of the sustained efficacy and impact on reproductive outcomes, including the pattern of ovulation and offspring health, is warranted. This review consolidated present findings and emphasized areas for further exploration to better inform clinical decision-making and future research directions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.